ESC Premium Access

Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

Presentation

About the speaker

Doctor Kazuma Oyama

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
0 follower

17 more presentations in this session

Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants

Speaker: Mr A. Holt (Copenhagen, DK)

Thumbnail

Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates

Speaker: Mr A. Holt (Copenhagen, DK)

Thumbnail

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

Speaker: Mr Q. Ying (Perth, AU)

Thumbnail

Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

Speaker: Doctor M. Delbeck (Wuppertal, DE)

Thumbnail

Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial

Speaker: Assistant Professor H. Fukaya (Sagamihara, JP)

Thumbnail

Access the full session

Congress committee e-posters choice in pharmacology and pharmacotherapy

Speakers: Doctor K. Oyama, Mr A. Holt, Mr A. Holt, Mr Q. Ying, Doctor M. Delbeck...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

A closer look at heart failure drugs: particular benefits and problems.

27 August 2021

ESC Premium Access

The practicalities of drug treatment in heart failure - Chat Moderator.

27 August 2021

ESC Premium Access

Heart failure as a complication of covid-19 infection: systematic review and meta-analysis

27 August 2021

This platform is supported by

logo Novo Nordisk